

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re the Application of: Loscalzo**

**Application No.: Not Yet Assigned**

**Filed: October 20, 2003**

**For: Methods of Treating Vascular Diseases Characterized by Nitric Oxide Insufficiency**

**Docket No: 102258.170US1**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 Form.

A copy of each of the cited references is not submitted herewith since they were filed and/or cited in one of the applications to which the present application claims priority. 37 CFR § 1.98(d).

The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art.

This Information Disclosure Statement is being submitted before the mailing date of a first office action on the merits or a notice of allowance. Accordingly, no fee is due.

Applicants respectfully request that the Examiner initial and return a copy of the enclosed PTO-1449 Form with the next communication from the Patent Office.

Respectfully submitted,

Edward D. Grieff  
Registration No. 38,898

Date: October 20, 2003  
HALE AND DORR LLP  
1455 Pennsylvania Avenue, NW  
Washington, DC 20004  
Phone: (202) 942-8400

Please type a plus sign (+) inside this box

1

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

## Sheet

1

of

5

**Complete If Known**

Application Number	10/415,136
Filing Date	April 25, 2003
First Named Inventor	Loscalzo
Group Art Unit	
Examiner Name	
Attorney Docket Number	102258.170US1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2 of

5

## Complete If Known

Application Number	10/415,136
Filing Date	April 25, 2003
First Named Inventor	Loscalzo
Group Art Unit	
Examiner Name	

Attorney Docket Number 102258.170 US1

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Dupuis, Cardiovascular Drugs and Therapy, 8(3):501-507 (1994).	
		Cohn et al, The New England Journal of Medicine, 325(5):303-310 (1991).	
		Cohn et al, The New England Journal of Medicine, 314(24):1547-1552 (1986).	
		Carson et al, Circulation, Supplement I, 92(8):I31-I32, Abstract No. 0145 (1995).	
		Francis et al, Circulation, Supplement VI, 87(6):VI40-VI48 (1993).	
		Pierpont et al, Chest, 73(1):8-13 (1978).	
		Massie et al, The American Journal of Cardiology, 40:794-801 (1977).	
		Kaplan et al, Annals of Internal Medicine, 84:639-645 (1976).	
		Bauer et al, Circulation, 84(1):35-39 (1991).	
		The SOLVD Investigators, The New England Journal of Medicine, 327(10):685-691 (1992).	
		Ziesche et al, Circulation, 87(6):VI56-VI64 (1993).	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

5

## Complete If Known

Application Number	10/415,136
Filing Date	April 25, 2003
First Named Inventor	Loscalzo
Group Art Unit	
Examiner Name	

Attorney Docket Number 102258.170 US1

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Rector et al, Circulation, 87(6):VI71-VI77 (1993).	
		Carson et al, Journal of Cardiac Failure, 5(3):178-187 (September 10, 1999).	
		Dries et al, The New England Journal of Medicine, 340(8):609-616 (February 25, 1999).	
		Freedman et al, Drugs, 54(Supp. 3):41-50 (1997).	
		Sherman et al, Cardiologia, 42(2):177-187 (1997).	
		Biegelson et al, Coronary Artery Disease, 10-241-256 (1999).	
		Rudd et al, Am. J. Physiol., 277(46):H732-H739 (1999).	
		Hamerman et al, Am. J. Physiol., 277(46):H1579-H1592 (1999).	
		Loscalzo et al, Transactions of the American and Climatological Ass., 111:158-163 (2000).	
		Burnier et al, Hypertension, 22(3):339-347 (September 1993).	
		von Lutterotti et al, American Journal of Hypertension, 4(4 Part 2):346S-349S (1991).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4 of 5

**Completion If Known**

Application Number	10/415,136
Filing Date	April 25, 2003
First Named Inventor	Loscalzo
Group Art Unit	
Examiner Name	

Attorney Docket Number 102258.170 US2

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Johnson, Clinical Pharmacy, Vol. 5, pages 536 and 541 (1986).	
		Massie et al, Br. Heart J., 45:376-384 (1981).	
		Turner et al, The American Journal of Cardiology, 47:910-916 (1981).	
		Massie et al, Circulation, 63(3):658-664 (1981).	
		Nelson et al, Journal of Cardiovascular Pharmacology, 5(4):574-579 (1983).	
		Leier et al, Circulation, 63(1):102-109 (1981).	
		Wilson et al, The American Journal of Medicine, 71:627-633 (1981).	
		Biddle et al, J. Clin. Pharmacol., 21:343-350 (1981).	
		Magorien et al, Clinical Research, 27(4):A617 (1979).	
		Turner et al, Clinical Research, 29(2):246A (1981).	
		Hibiya et al, Japanese Circulation Journal, 45:966 (Abstract No. 338) (1981).	

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/415,136
(use as many sheets as necessary)		Filing Date	April 25, 2003
		First Named Inventor	Loscalzo
		Group Art Unit	
		Examiner Name	
Sheet	5	of	5
		Attorney Docket Number	

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.